Selective laser trabeculoplasty as a first-line therapy: A review

Michael Waisbourd*, L. Jay Katz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Poor adherence with glaucoma medications has been well documented. There remains a significant unmet need for a relatively safe intraocular pressure (IOP)-lowering procedure that minimizes or eliminates patient participation, and thus reduce the incidence of treatment failures attributable to nonadherence. Selective laser trabeculoplasty (SLT) offers several advantages: It effectively reduces IOP in most patients with open-angle glaucoma, it is cost-effective compared with eye drops, it can be repeated if needed, and it eliminates the issue of adherence to medications when used as an initial treatment. This article reviews the evidence supporting the use of SLT as a first-line therapy in glaucoma.

Original languageEnglish
Pages (from-to)519-522
Number of pages4
JournalCanadian Journal of Ophthalmology
Issue number6
StatePublished - 1 Dec 2014
Externally publishedYes


Dive into the research topics of 'Selective laser trabeculoplasty as a first-line therapy: A review'. Together they form a unique fingerprint.

Cite this